BioMarin Pharmaceutical (NASDAQ:BMRN) versus CollPlant Biotechnologies (NASDAQ:CLGN) Head-To-Head Comparison

BioMarin Pharmaceutical (NASDAQ:BMRN) and CollPlant Biotechnologies (NASDAQ:CLGN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Volatility and Risk

BioMarin Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Earnings & Valuation

This table compares BioMarin Pharmaceutical and CollPlant Biotechnologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22 billion	3.36	$348.90 million	$0.37	151.22
CollPlant Biotechnologies	$318,000.00	21.82	-$11.49 million	($13.59)	-0.27

BioMarin Pharmaceutical has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioMarin Pharmaceutical and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

Insider & Institutional Ownership

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for BioMarin Pharmaceutical and CollPlant Biotechnologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1	6	16	3	2.81
CollPlant Biotechnologies	1	1	0	0	1.50

BioMarin Pharmaceutical currently has a consensus target price of $88.60, indicating a potential upside of 58.36%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 3,169.75%. Given CollPlant Biotechnologies’ higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than BioMarin Pharmaceutical.

Summary

BioMarin Pharmaceutical beats CollPlant Biotechnologies on 11 of the 15 factors compared between the two stocks.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.